Therefore, the first aim of our experiment was to establish whether the PECAM-1/thrombus ratio calculated in the flow chamber model (without endothelium) differs from that calculated in the intravital thrombosis model (with endothelium) and, hence, whether this parameter in combination with the flow chamber may be a reliable tool for the assessment of ex vivo platelet activity in pathological states such as inflammation. This evidence concerns the gene PECAM1 and Venous thrombosis.